GRFS Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of 7.69% compared to Grifols SA's net margin of 1.68%. Grifols SA's return on equity of 5.73% beat Cellectis SA's return on equity of -31.08%.

Grifols SA has a consensus price target of $11.25, signalling upside risk potential of 27.12%. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 51.9%. Given that Cellectis SA has higher upside potential than Grifols SA, analysts believe Cellectis SA is more attractive than Grifols SA.

Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.784%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.96%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than Cellectis SA quarterly revenues of $35M. Grifols SA's net income of $167.6M is higher than Cellectis SA's net income of $586.4K. Notably, Grifols SA's price-to-earnings ratio is 14.41x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.72x versus 5.90x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 7.69% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 5.73% beat DBV Technologies SA's return on equity of -280.59%.

Grifols SA has a consensus price target of $11.25, signalling upside risk potential of 27.12%. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 47.98%. Given that DBV Technologies SA has higher upside potential than Grifols SA, analysts believe DBV Technologies SA is more attractive than Grifols SA.

Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.96%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than DBV Technologies SA quarterly revenues of --. Grifols SA's net income of $167.6M is higher than DBV Technologies SA's net income of -$33M. Notably, Grifols SA's price-to-earnings ratio is 14.41x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.72x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of 7.69% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 5.73% beat NuCana Plc's return on equity of -286.82%.

Grifols SA has a consensus price target of $11.25, signalling upside risk potential of 27.12%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 498700.96%. Given that NuCana Plc has higher upside potential than Grifols SA, analysts believe NuCana Plc is more attractive than Grifols SA.

Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.96%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than NuCana Plc quarterly revenues of --. Grifols SA's net income of $167.6M is higher than NuCana Plc's net income of -$378.9K. Notably, Grifols SA's price-to-earnings ratio is 14.41x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.72x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech Plc has a net margin of 7.69% compared to Grifols SA's net margin of -31.41%. Grifols SA's return on equity of 5.73% beat Trinity Biotech Plc's return on equity of --.

Grifols SA has a consensus price target of $11.25, signalling upside risk potential of 27.12%. On the other hand Trinity Biotech Plc has an analysts' consensus of -- which suggests that it could grow by 1462.5%. Given that Trinity Biotech Plc has higher upside potential than Grifols SA, analysts believe Trinity Biotech Plc is more attractive than Grifols SA.

Grifols SA has a beta of 0.671, which suggesting that the stock is 32.935% less volatile than S&P 500. In comparison Trinity Biotech Plc has a beta of 0.489, suggesting its less volatile than the S&P 500 by 51.129%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.96%. Trinity Biotech Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Trinity Biotech Plc pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than Trinity Biotech Plc quarterly revenues of $15.2M. Grifols SA's net income of $167.6M is higher than Trinity Biotech Plc's net income of -$4.8M. Notably, Grifols SA's price-to-earnings ratio is 14.41x while Trinity Biotech Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.72x versus 0.23x for Trinity Biotech Plc. Usually stocks with elevated PS ratios are considered overvalued.